Ingenuity Systems Announces Toxicogenomics Best Practices White Paper

REDWOOD CITY, California, August 17, 2010 - Ingenuity(R) Systems, the leading provider of information solutions for
life science researchers, today announced the release of the white paper,
"Best Practices for Assessing Toxicity throughout the Drug Discovery Process:
Toxicogenomics." The white paper is based on input from industry experts and
shows how multidisciplinary toxicology teams in drug discovery can leverage
toxicogenomics and IPA(R) for improved predictive toxicology and mechanistic
toxicity analysis.

Understanding the basic biological mechanisms related to toxicity is a
top priority for both traditional toxicologists and other researchers whose
understanding of toxicity can inform decision making at all phases of a
research project. By complementing a traditional toxicological approach with
toxicogenomics, researchers get a better interpretation of large, complex
amounts of data with lots of variables, can detect toxicity earlier in drug
discovery for faster project decisions, and - most significantly - can better
understand molecular level events that underlie toxicity.

Dr. Phil Hewitt, Head of Toxicogenomics at Merck-Serono, believes that
gene expression profiling has the greatest potential for improving
mechanistic insight and therefore adds a high value to Tox and Safety
studies. According to Dr. Hewitt, "Implementing toxicogenomics with
traditional tox approaches will help researchers detect toxicity earlier.
Assessing toxicity is not always clear, and incorporating another source of
information can only complement traditional animal studies."

IPA-Tox(R), a capability within IPA, is the industry leading
toxicogenomics software solution for analyzing this type of expression data
to obtain actionable insights. With IPA-Tox, scientists can analyze large
scale datasets (genomic and proteomic datasets, dose response datasets, etc.)
in order to identify the key functions and pathways that are activated or
disrupted upon treatment with a compound. IPA-Tox also links expression data
to clinical pathology endpoints for mechanistic hypotheses generation and
identification of mechanism of toxicity.

To download the complimentary white paper and learn more about
toxicogenomics best practices using IPA, please go to:
pages.ingenuity.com/BestPracticesToxicity.html

The latest release of IPA includes a significant increase in molecular
toxicology content with a focus on key clinical and pre-clinical pathology
endpoints as prioritized by customers across key tissues of liver, kidney,
and heart. You can sign up for a free trial of IPA-Tox at:
pages.ingenuity.com/IPA_Toxicity_Trial.html

About IPA(R)

IPA is an all-in-one software application that enables researchers to
model, analyze, and understand the complex biological and chemical systems at
the core of life science research.

For more information visit: www.ingenuity.com

About Ingenuity(R) Systems

Ingenuity Systems is a leading provider of information solutions and
custom services for life science researchers, computational biologists and
bioinformaticists, and life science industry suppliers. For more information
visit: www.ingenuity.com

Heidi Bullock, Director, Marketing of Ingenuity Systems, +1-650-381-5150